Clinical trials: Metastatic Renal Cancer
Renal Cell Carcinoma (RCC)
FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
In renal cell carcinoma (RCC) patients, lymph node metastases detection and treatment are the most critical issues in daily clinical decision-making.
- Trial name
- FAZA (NCT03955393)
- Testing
- 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS San Raffaele
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of pembrolizumab combined with axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma.
- Trial name
- PANDORA (NCT04995016)
- Testing
- Pembrolizumab, Axitinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Second Hospital
Renal Cell Carcinoma
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
The purpose of this study is to determine the safety and efficacy of combined stereotactic body radiotherapy (SBRT) + sorafenib in the treatment of patients with Stage IV renal cell carcinoma (RCC) who have recurred locally…
- Trial name
- NCT00672178
- Testing
- Stereotactic body radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Kidney Cancer, Melanoma (Skin)
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer…
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00003308
- Testing
- stereotactic radiosurgery
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Renal Cell Carcinoma
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with…
- Trial name
- NCT05188118
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014274
- Testing
- carboplatin, gemcitabine hydrochloride, methotrexate
- Where
- 29 sites in Austria, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Renal Cell Cancer, Renal Cell Carcinoma
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic…
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00684996
- Testing
- etaracizumab, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC
- Trial name
- NCT00591188
- Testing
- capecitabine, interferon-alpha
- Where
- Russia
- Volunteers
- 49 people
- Sponsor
- Kidney Cancer Research Bureau
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Metastatic Kidney Cancer, Metastatic Renal Cell Carcinoma
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
One third of patients with kidney cancer are diagnosed in the metastatic stage, and among patients with a localized form, about 30 to 40% will develop metastases after surgery.
- Trial name
- CA9CRM (NCT00942058)
- Testing
- Serum and urinary CA9 level
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Metastatic Renal Cell Cancer, GIST
Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
Patients with advanced kidney cancer or GIST (Gastro Intestinal Stromal Tumor: this is a tumor of the intestines) may be eligible for treatment with one of the following drugs: sunitinib (Sutent ®) or sorafenib (Nexavar ®).
- Trial name
- NCT01246843
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Metastatic Renal Cell Carcinoma
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on…
- Trial name
- NCT00444314
- Testing
- Panzem® NCD, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- CASI pharmaceuticals, Inc.
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal…
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma
- Trial name
- NCT06479811
- Testing
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.